Catatonia: Current Perspectives on Pathophysiology, Clinical Features, and Therapeutic Strategies

Catatonia is a complex neuropsychiatric syndrome characterized by a spectrum of motor and behavioral symptoms, including stupor, catalepsy, and agitation. This review examines the current understanding of catatonia, focusing on its clinical presentation, pathophysiology, and treatment options. Catatonia can manifest in various forms, including motor abnormalities, altered mental status, and mood disturbances. Symptoms often include immobility, echolalia, and posturing, which may severely impact daily functioning and quality of life. The pathophysiology of catatonia involves disruptions in neural circuits, particularly in the supplementary motor area and prefrontal cortex. Key neurotransmitter systems, including GABAergic and glutamatergic pathways, are implicated. NMDA receptor dysfunction and autoimmune mechanisms are also significant areas of research. Prompt diagnosis and intervention are critical for favorable outcomes. Short-term treatment often includes benzodiazepines and electroconvulsive therapy (ECT), which can lead to rapid symptom resolution. Long-term outcomes vary based on the underlying condition and the duration of untreated catatonia. Untreated catatonia can lead to severe complications, including permanent neurological damage and progression to malignant catatonia. Advances in understanding catatonia are ongoing. Future research should focus on molecular and cellular mechanisms, genetic and epigenetic factors, and novel therapeutic interventions. Longitudinal studies are needed to assess the durability and safety of current treatments and to explore new approaches such as transcranial magnetic stimulation, deep brain stimulation, and emerging pharmacological agents. Further epidemiological studies are also necessary to determine the prevalence of catatonia across different populations and settings, considering cultural, environmental, and socioeconomic factors.Keywords: Catatonia, neuropsychiatric syndrome, benzodiazepines, NMDA receptor antagonists, multidisciplinary approach